CN1714850A - Use of medicinal composition containing ligusticum wallichii for treating chronic brain blood supply deficiency - Google Patents
Use of medicinal composition containing ligusticum wallichii for treating chronic brain blood supply deficiency Download PDFInfo
- Publication number
- CN1714850A CN1714850A CN 200410019828 CN200410019828A CN1714850A CN 1714850 A CN1714850 A CN 1714850A CN 200410019828 CN200410019828 CN 200410019828 CN 200410019828 A CN200410019828 A CN 200410019828A CN 1714850 A CN1714850 A CN 1714850A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma
- blood supply
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001684 chronic effect Effects 0.000 title claims abstract description 33
- 230000036770 blood supply Effects 0.000 title claims abstract description 30
- 210000004556 brain Anatomy 0.000 title abstract description 26
- 239000000203 mixture Substances 0.000 title abstract description 5
- 230000007812 deficiency Effects 0.000 title abstract 2
- 241000112528 Ligusticum striatum Species 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 32
- 230000002490 cerebral effect Effects 0.000 claims description 38
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 241000628997 Flos Species 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 8
- 235000019634 flavors Nutrition 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 235000014435 Mentha Nutrition 0.000 claims description 7
- 241001072983 Mentha Species 0.000 claims description 7
- 241000545442 Radix Species 0.000 claims description 7
- 241001180876 Saposhnikovia Species 0.000 claims description 7
- 208000014644 Brain disease Diseases 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 208000012886 Vertigo Diseases 0.000 claims 1
- 231100000889 vertigo Toxicity 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 abstract description 31
- 230000006386 memory function Effects 0.000 abstract description 8
- 230000010412 perfusion Effects 0.000 abstract description 8
- 210000001168 carotid artery common Anatomy 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 2
- 238000011552 rat model Methods 0.000 abstract description 2
- 210000002784 stomach Anatomy 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 28
- 239000007788 liquid Substances 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 16
- 238000011534 incubation Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 10
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 10
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical group COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 230000004087 circulation Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 230000003727 cerebral blood flow Effects 0.000 description 6
- 238000004821 distillation Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 230000035939 shock Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 5
- 206010061216 Infarction Diseases 0.000 description 5
- 241001484259 Lacuna Species 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 230000007574 infarction Effects 0.000 description 5
- 206010063452 arteriosclerotic retinopathy Diseases 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 210000001320 hippocampus Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229960000715 nimodipine Drugs 0.000 description 4
- 206010040560 shock Diseases 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 102000009660 Cholinergic Receptors Human genes 0.000 description 3
- 108010009685 Cholinergic Receptors Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 229940126678 chinese medicines Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- -1 stir Substances 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 238000002585 cerebral angiography Methods 0.000 description 2
- 210000004720 cerebrum Anatomy 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000001652 frontal lobe Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 206010008097 Cerebral circulatory failure Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 201000006559 Vertebrobasilar insufficiency Diseases 0.000 description 1
- KUQFEFIFTUHBJE-UHFFFAOYSA-N [Cl].C=1C=CSC=1 Chemical compound [Cl].C=1C=CSC=1 KUQFEFIFTUHBJE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001841 basilar artery Anatomy 0.000 description 1
- 201000010861 basilar artery insufficiency Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000009570 retrograde amnesia Diseases 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention belongs to the field of medicine technology, and is especially the new use of a kind of medicine composition in preparing medicine. The present invention establishes chronic brain blood supply deficiency rat model via tying common carotid artery on two sides and administrates the medicine composition through stomach perfusion. The test result shows that the medicine composition results in learning and memory function and dizziness latent phase of the rat obviously prior to the contrast group(P<0.05).
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of application of pharmaceutical composition in preparation treatment chronic insufficient cerebral blood supply medicine that contains Rhizoma Chuanxiong.
Background technology
The origin of notion
Chronic insufficient cerebral blood supply (Chronic Cerebral Circulation Inefficiency, CCCI) blood supply that refers to the brain integral level reduces the state of (being lower than 40-60ml/100g cerebral tissue/per minute), but not focal cerebrum ischemia.It is the new name of disease of year proposition surplus in the of external preceding 10.The old age or the presenium patient that often have some to tell subjective symptomss such as nose heave, dizziness repeatedly clinically, except ocular fundus arteriosclerosis, both also not have cranium brain CT unusual for the focal sign of impassivity infringement, and these patients often are diagnosed as " cerebral arteriosclerosis ".As everyone knows, there are difference in the notion of cerebral arteriosclerosis and clinical diagnosis standard long-term.The chaos of conception that the so-called cerebral arteriosclerosis name of disease of always using for fear of people causes, Japanese health ministry has entrusted " about the definition and the diagnostic criteria tutorial class of cerebral arteriosclerosis disease " to study, cerebral arteriosclerosis has been made the corrigendum motion, think that previously cerebral arteriosclerosis, broad sense system include pathological notion of all diseases related that cerebral arteriosclerosis such as lacuna infarction causes; Narrow sense then refers to because cerebral arteriosclerosis causes the conscious slight neural mental symptom that is produced under the pathological state of disturbance of cerebral circulation, the focal sign of impassivity system and to stare at imaging examination unusual.The 16th apoplexy association of Japan formally was referred to as it chronic cerebral circulatory failure (Chronic Cerebral Circulation Inefficiency), i.e. CCCI in 1991.
International research shows that the harm of chronic insufficient cerebral blood supply is a lot.Specifically be summarized as follows:
● the atrophy of cortex atrophy----cortex is the basic pathological change that causes senile dementia
● the neurogenous degeneration of Hippocampus
● frontal lobe, Hippocampus M type cholinoceptor combination rate decline alba are loosened--and-Yi causes occurring hypomnesis, retrograde amnesia occurs
● glial cells hyperplasia---cause brain function to descend
● capillary bed changes
● other neural subjective symptoms obstacle
The diagnosis of CCCI
For CCCI is studied all sidedly, Japan scholar horizontal well is divided into 3 groups with the age the old man more than 60 years old, the A group is: subjective symptoms outbreaks such as dizziness, carebaria are arranged, more than the ocular fundus arteriosclerosis KWII, but do not have also Non Apparent Abnormality person of any focal neurosigns, CT scan; The B group is: except that subjective symptomss such as no dizziness, other conditions are identical with the A group: the C group is cotemporary healthy old men.These three groups are all carried out CT, MRI, TCD and PET and check. and check result is: (1) TCD measures common carotid artery blood flow and shows.The A group all significantly lowers for two groups than B, C; (2) PET shows Interhemispheric blood flow, and the A group significantly lowers than the C group; (3) MRI finds to have in the A group 55%, has 15% old man to find to have cerebral infarction or lacuna infarction in B and the C group.Its conclusion is: cerebral blood flow lowers near normal 80%, subjective symptomss such as dizziness just may occur; The appearance of mental symptom and nervous symptoms then must be lower than below 80% by blood flow.It should be noted that. the patients' of these dizzy outbreaks TCD and PET to be checked find. the blood flow in carotid artery system and cerebral hemisphere perfusion district thereof and the blood flow of vertebra basilar artery lower equally, therefore clinically dizzy symptom is belonged to vertebro-basilar artery insufficiency without exception seem comprehensive inadequately.Japanese health ministry blood circulation diseases tutorial class (1990) is studied the diagnostic criteria of having worked out CCCI in view of the above, sees the following form 1.
Table 1 chronic insufficient cerebral blood supply (CCCI) diagnostic criteria (one)
Since subjective symptoms undulatory property growth and decline such as that the circulatory disturbance of brain causes is nose heave, dizziness, but diagnostic imaging aspects such as clinical manifestation and CT all find no the finding of pointing out the vascular encephalosis, and do not belong to TIA category person.
1. clinical manifestation
(1) because various subjective symptomss (carebaria, dizziness etc.) the undulatory property growth and decline that the circulatory disturbance of brain causes.
(2) the focal sign of brain does not appear.
(3) most accompanied with hypertension.
(4) the optical fundus tremulous pulse is arteriosclerosis and sexually revises.
(5) can hear vascular murmur at the perfusion tremulous pulse.
2.CT finding " does not see that the vascular encephalosis becomes ".
Other
(1) cerebral angiography or cervical region TCD etc. show brain perfusion arterial occlusion or narrow change.
(2) cerebral circulation is measured and is shown that blood flow lowers.
(3) age is basically more than 60.
(4) got rid of other disease that can cause above-mentioned subjective symptoms definitely.
(1996) such as nearly rattans make further research 60 routine CCCI patients with said method, except that obtaining above-mentioned similar result of study, still observing CCCI patient further descends with the age growth common carotid artery blood flow, the all sites cerebral blood flow of each cerebral lobe and brain oxidative metabolism rate all descend obviously, think because atherosclerosis risk factors such as hypertension have caused the sclerosis of the mobile arteries and veins of brains.Cause diffuse cerebral blood flow and brain poor metabolism to produce the subjective symptoms of CCCI.Performance is not focal in view of the CCCI cerebral lesion, thus do not occupy transient ischemic attack (transient ischemic attack) category, and drawn more practical CCCI diagnostic criteria (seeing the following form 2).
Table 2 chronic insufficient cerebral blood supply (CCCI) diagnostic criteria (two)
1. subjective symptomss such as nose heave, dizzy, different fiber crops are arranged
2. the finding of supporting cerebral arteriosclerosis is arranged.
(1) with hypertension, ocular fundus arteriosclerosis change etc.
(2) vascular murmur of audible and brain perfusion tremulous pulse sometimes.
3. do not see the focal neurosigns of brain.
4. type CT or MRI check that affirmation does not have the cerebral lesion of the device matter of vascular.
5. get rid of because the above-mentioned subjective symptoms that other disease causes.
6. the age is in principle greater than 60 years old.
7. the cerebral circulation inspection confirms that cerebral blood flow is low.
8. definite brain perfusion tremulous pulse such as cerebral angiography, cervical region TCD has obturation, narrow sick.
Be born in 2000 the up-to-date diagnostic criteria of CCCI, its particular content is as follows:
" CCCI diagnostic criteria " version in 2000
1. subjective symptomss such as dizziness, headache, head sink;
2. the finding of supporting cerebral arteriosclerosis is arranged: (1) is with hypertension, ocular fundus arteriosclerosis change etc.; Or the vascular murmur of (2) audible and brain perfusion sometimes tremulous pulse;
3. the focal neurosigns that does not have brain;
4.CT having the organic brain of vascular, MRI do not change;
5. get rid of the above-mentioned subjective symptoms that other diseases causes;
6. the age is in principle greater than 60 years old (can be loosened to more than 45 years old);
7. cerebral circulation confirms that cerebral blood flow is low;
8.DSA or TCD prompting brain perfusion tremulous pulse has inaccessible or narrow change.
Compare with early stage version diagnostic criterias in 96 years, this edition standard is opinion, clear and definite more.Its typing sees the following form 3.
The international typing of table 3 chronic insufficient cerebral blood supply
I type: simple chronic insufficient cerebral blood supply
II type: the change of CCCI+ brain essence (MRI CT find the lacuna infarction)
Over past ten years, domestic many scholars compare comprehensive clinical research to CCCI, the blood properties such as blood viscosity fluid rheology index of observing most of CCCI patients reaches Fibrinogen unusually and obviously raises, and thinks that these also have bigger influence to the formation of CCCI or the fluctuation of symptom unusually; CT sees at the end unusual many patients. cranium brain MRI often can detect ischemic focus (the T1 weighted signal is no abnormal, T2 weighting and proton become to protect the slightly high signal of visible stigma point-like); Adopt the TCD dynamic measurement except that common carotid artery, main vascular flow lowers in the brain of still visible many places, for the clinical diagnosis of CCCI has increased new content.
The treatment of CCCI
According to table 1 and table 3, all dizzinesses that the undulatory property growth and decline are arranged, subjective symptoms such as nose heave, CT, MRI do not see vascular brain organic focus person, should belong to simple property CCCI, be considered to the cerebral infarction state of generation last stage, be necessary to carry out positive control, need improve the risk factor (as hypertension, diabetes, hyperlipemia, obesity etc.) of cerebral circulation and removal ischemic cerebrovascular (ICW), preferably adjoin anti-platelet aggregation medicines such as pyridine with aspirin, thiophene chlorine simultaneously, several days clinical subjective symptomss.And TCD or PET measure brain trunk tremulous pulse are arranged (vertebra-basilar artery system or/carotid artery system) blood flow reduction person, belong to compensatory phase CCCI, should take corresponding prevention and health care measure at the ICVD risk factor that exists, symptoms such as clinical appearance dizziness, CT shows ischemic brain material change (cerebral infarction, lacuna infarction), and TCD or PET confirm to have cerebral blood flow attenuating person.Then belong to CCCIII type or III type, should press lacuna infarction or cerebral infarction respectively and handle.
At present, the medicine for the treatment of the CCCI use clinically has: THA: cholinesterase inhibitor, GST-21: maincenter type N cholinoceptor inhibitor, FK506: immunosuppressant, Nimsuperzine:Cox-2 inhibitor etc., all obtained recent preferably clinical efficacy, late result remains further to be studied.Traditional Chinese medicine of China is having unique effect aspect the treatment CCCI.
The Chinese medicine medicine that dispels the wind is the medicine that ancient Chinese medicine doctor is used always, has effects such as dispelling exopathogens from superficies of the body, expelling wind and removing dampness, freeing lung-Qi and eliminating damp.Modern pharmacology confirms that the medical instrument that dispels the wind has the expansion coronary artery, increases coronary flow, reduces myocardial oxygen consumption, bring high blood pressure down, and fortifying fibre protein dissolution activity, the anticoagulation system, microcirculation improvement, effects such as smooth muscle spasm are alleviated in blood pressure lowering.The clinical effect of Rhizoma Chuanxiong in the medicine, Radix Salviae Miltiorrhizae, Herba Asari, Herba Schizonepetae, Radix Saposhnikoviae, Rhizoma Gastrodiae etc. of dispeling the wind is constantly expanded.
Through secular clinical practice, choose the pharmaceutical composition of forming by Rhizoma Chuanxiong, the Radix Angelicae Dahuricae, Rhizoma Et Radix Notopterygii, Herba Menthae etc. by the people, had the effect of rapid releasing headache, blood circulation promoting and blood stasis dispelling, dispelling wind and relieving, be used for various headaches clinically, not only can relief of symptoms, life-time service also has the effect of healing.
But relevant this medicine composite for curing chronic insufficient cerebral blood supply effect does not appear in the newspapers as yet.
Summary of the invention
The object of the invention is to provide the new purposes of aforementioned pharmaceutical compositions aspect the treatment chronic insufficient cerebral blood supply.
The prescription of this pharmaceutical composition is formed as follows by weight ratio:
50～200 parts of Rhizoma Chuanxiongs, 20～80 parts of the Radixs Angelicae Dahuricae, 20～80 parts of Rhizoma Et Radix Notopterygiis, 5～20 parts of Herba Asaris, 50～150 parts of Herba Menthaes, 10～50 parts of Radix Saposhnikoviaes, 10～50 parts in Radix Glycyrrhizae, 40～90 parts of Folium Camelliae sinensis, 30～100 parts of Radix Paeoniae Rubra, 10～50 parts in Rhizoma Gastrodiae, 20～90 parts of Flos Chrysanthemis.
Best proportioning is:
127 parts of Rhizoma Chuanxiongs, 42 parts of the Radixs Angelicae Dahuricae, 42 parts of Rhizoma Et Radix Notopterygiis, 10 parts of Herba Asaris, 84 parts of Herba Menthaes, 15 parts of Radix Saposhnikoviaes, 21 parts in Radix Glycyrrhizae, 63 parts of Folium Camelliae sinensis, 53 parts of Radix Paeoniae Rubra, 21 parts in Rhizoma Gastrodiae, 53 parts of Flos Chrysanthemis.
Aforementioned pharmaceutical compositions can be made any one dosage form on the pharmaceutics, and wherein oral liquid is implemented by following scheme:
The material of getting it filled according to the above ratio: Rhizoma Chuanxiong 127g, Radix Angelicae Dahuricae 42g, Rhizoma Et Radix Notopterygii 42g, Herba Asari 10g, Herba Menthae 84g, Radix Saposhnikoviae 15g, Radix Glycyrrhizae 21g, Folium Camelliae sinensis 63g, Radix Paeoniae Rubra 53g, Rhizoma Gastrodiae 21g, Flos Chrysanthemi 53g; Six-element Chinese medicines such as Rhizoma Chuanxiong, Rhizoma Et Radix Notopterygii, Herba Asari, Herba Menthae, Radix Saposhnikoviae, Flos Chrysanthemi are added 10 times of amounts of water, hydrodistillation is collected Aromatic water 800ml, aqueous solution after distillation device is in addition collected, medicinal residues and Radix Glycyrrhizae, the Radix Angelicae Dahuricae, Radix Paeoniae Rubra, Rhizoma Gastrodiae four flavors add 8 times of amounts of water and decoct twice, each decocting time is 1 hour, merge decocting liquid, filter; Filtering residue discards, and Folium Camelliae sinensis adds 12 times of amounts of fresh boiling water and soaks twice, and each soak time is 20 minutes, merge leachate, filter, the aqueous solution after filtrate and above-mentioned decocting liquid and the distillation merges, relative density is 1.14 when being evaporated to 70 ℃, leaves standstill, and adds 2 times 95% ethanol after being cooled to room temperature, stir, cold preservation 24 hours makes precipitation, gets the supernatant concentrating under reduced pressure and reclaims ethanol, leave standstill, get supernatant and filter, filtrate is concentrated into that relative density is 1.18 under the room temperature, with above-mentioned Aromatic water with 0.8% tween 80 solubilising, add in the above-mentioned concentrated solution, stir, water is adjusted to 980ml, is being adjusted to 4.5～6.5 with 10%NaOH, adding the adjustment total amount to 1000ml, stir, leave standstill, filter, sterilization, promptly.
Chronic insufficient cerebral blood supply (CCCI) has close getting in touch with brain symptoms such as dizziness, headaches, but at aspects such as pathogenesis and Therapeutic Method tangible difference is arranged again.At present, for chronic insufficient cerebral blood supply, also mainly be based on the pharmaceutical intervention treatment, there is not clear and definite medicine.The medicine of treatment headache not necessarily has the effect of treatment chronic insufficient cerebral blood supply, even also can cause other untoward reaction.
In order to understand the present invention better, oral liquid formulation (hereinafter to be referred as " oral liquid ") treatment chronic insufficient cerebral blood supply rat model below by the observation aforementioned pharmaceutical compositions is dizzy, the influence of learning and memory, and the therapeutical effect of this pharmaceutical composition aspect the treatment chronic insufficient cerebral blood supply is described.
Experimental example: this medicine composite for curing chronic insufficient cerebral blood supply experimentation
One, materials and methods
1. animal grouping: 100 of male SD rats, in 10 ages in week, body weight 250 ± 20g is divided into 3 groups at random: oral liquid group, nimodipine group, model control group, every group each 20.Oral liquid group 8 weeks after modeling began to gavage this pharmaceutical composition 2g/kg/ days, once a day, and continuous 4 weeks; The nimodipine group substitutes oral liquid with equal-volume nimodipine (500ug/kg), and is surplus with the oral liquid group; Model control group substitutes oral liquid with the equal-volume normal saline, and is surplus with the oral liquid group.Medicine: nimodipine, nimodipine tablet, Shanxi Yabao Pharmaceutical Co., Ltd. produces, and lot number is that the accurate word (196) of medicine is defended No. 048095 in the Shanxi, every day 3 times, each 20mg, oral; This drug composition oral liquid is according to embodiment 1 method production.
2. rat chronic cerebral blood supply insufficiency model development: with reference to Torre[Torre Jc, Fortin t, park GA, et al.ChroniccereBRovascular insufficiency induces dementia-induces dementia-like deficits in agedrats.Brain Res, 1992,582 (2): 186-195.] etc. method is made rat both sides ligation of carotid models (2VO).Rat is got the cervical region median incision and cuts off skin through being fixed in behind the 10% chloral hydrate 3.0ml/kg intraperitoneal injection of anesthesia on the operation plate, and passivity is separated each layer tissue, see in the neck that the external carotid artery bifurcated separates vagus nerve, prick bilateral common carotid arteries, layer-by-layer suture with the 4-0 toe-in.Keep 37 ℃-38 ℃ of anus temperature, 23 ℃ of postoperative feeding environment temperature, free diet in the art.
3. learning and memory is measured: adopt Y type maze experiment.Rat is placed in the Y type labyrinth box, began experiment after conforming 3 minutes.The rat of shocking by electricity successively clockwise, the learning and memory in rats achievement has 9 correct required number of shocks to represent to reach in continuous 10 times, how much represent the quality of learning and memory function with reaching 9/10 correct required number of shocks.Laboratory animal respectively at 2VO before, respectively carry out Y type labyrinth test and record achievement behind the 2VO behind 8 weeks, the 2VO behind 12 weeks, the 2VO 16 weeks.
4. measure dizzy incubation period: regulate rotation inducing instrument rotary speed 200r/min.The rat rotation was placed in charged insulating 50 * 50 * 40 experimental boxs on every side in bottom in 1 minute, at once electric shock.(cylindrical rubber of the high 10cm of a diameter 6.5cm is put by experimental box central authorities).Rat stops to jumping onto rubber column escape electric shock and keeping being dizzy incubation period in 30 seconds at rubber column from rotation.Incubation period, long prompt was dizzy serious more more.Each measured once dizzy incubation period to all animals 16 weeks behind 12 weeks, the 2VO behind 8 weeks, the 2VO before 2VO, behind the 2VO.
Two, experimental result
1. oral liquid of the present invention is to the influence of chronic insufficient cerebral blood supply learning and memory function: Y shape maze test learning and memory in rats achievement has 9 correct required number of shocks to represent to reach before all rat modelings in continuous 10 times, how much represents the quality of learning and memory function with reaching 9/10 correct required number of shocks.As shown in table 1, correct learning and memory function approximately needs about 18-20 time before the rat 2VO.Behind the rat 2VO, along with time lengthening, the learning and memory achievement descends gradually.The correct learning and memory achievement of 2VO12 week rat is electric shock about 39.5 times, and 16 weeks were about 58.3 times; Nimodipine group and 2VO group no significant difference, P＞0.05.12 weeks of oral liquid group, the correct learning and memory achievement with 16 weeks was that shock count is respectively 29.2 and 43.2 times, and organizing with 2VO relatively has notable difference, P＜0.05.Point out oral liquid of the present invention can effectively improve the 2VO learning and memory function.
Table 1 oral liquid of the present invention is to the influence of chronic insufficient cerebral blood supply learning and memory function
| Group | n | Learning and memory achievement (X ± SD time) | |||
| Before the 2VO | 8 weeks behind the 2VO | 12 weeks behind the 2VO | 16 weeks behind the 2VO | ||
| The 2VO group | 15 | 8.6±2.1 | 17.3±2.3 | 39.5±4.3 | 58.3±8.5 |
| The nimodipine group | 15 | 8.9±1.8 | 16.2±1.9 | 35.3±4.5 | 51.2±7.3 |
| The oral liquid group | 15 | 9.1±2.3 | 15.2±2.0 | 29.2±3.9* | 43.2±6.2* |
* compare P＜0.05 with the 2VO group
2. the influence that oral liquid of the present invention is dizzy to the chronic insufficient cerebral blood supply rat: as shown in table 2, be about 96 seconds dizzy incubation period before all rat modelings.Behind the rat 2VO, along with time lengthening increases dizzy incubation period.As shown in table 1, be respectively 17.3 ± 2.3,39.5 ± 4.3,58.3 ± 8.5 the dizzy incubation period that 2VO organizes 8 weeks, 12 weeks, 16 weeks, and notable difference arranged, P＞0.05 before the 2VO.Nimodipine treatment each time point of back and 2VO group no significant difference, P＞0.05.Be respectively correct 112.12 ± 16,127.41 ± 26,134.14 ± 31 the dizzy incubation periods in oral liquid group 12 week and 16 weeks, notable difference, P＜0.05 relatively arranged with the 2VO group.Point out oral liquid of the present invention can effectively improve dizzy effect incubation period of 2VO rat.
Table 2 oral liquid is to the dizzy preclinical influence of chronic insufficient cerebral blood supply rat
| Group | n | Dizzy incubation period (X ± SD second) | |||
| Before the 2VO | 8 weeks behind the 2VO | 12 weeks behind the 2VO | 16 weeks behind the 2VO | ||
| Sham operated rats | 15 | 96.24±12 | 95.21±19 | 96.24±12 | 95.21±19 |
| The 2VO group | 15 | 95.12±14 | 130.34±24# | 147.32+34# | 153.13±52# |
| The nimodipine group | 15 | 96.21±22 | 128.23±26 | 143.13±36 | 148.52±42 |
| The oral liquid group | 15 | 97.25±18 | 112.12±16* | 127.41±26* | 134.14±31* |
# and sham operated rats be P＜0.05 relatively; * compare P＜0.05 with the 2VO group
Three, discuss
1992, Torre etc. reported that at first ligation rat bilateral carotid causes the chronic insufficient cerebral blood supply model to succeed.Subsequently studies confirm that 2VO rat hippocampus CA1 district neural degeneration, cortex atrophy, white matter are loose, microglia hypertrophy and capillary bed change etc.The 2VO rat promptly enters chronic phase after 3 weeks, and frontal lobe appears to the 2VO3 rat in rat after 3 months, Hippocampus M type cholinoceptor combination rate descends, and monoamine class mediator changes and the energy metabolism compensatory activates and neuroethology changes.
This experimentation confirms that aspect learning and memory mensuration the correct learning and memory achievement in 12 weeks of oral liquid group of the present invention and 16 weeks is that shock count is respectively 29.2 and 43.2 times, with the 2VO group notable difference, P＜0.05 is arranged relatively.Point out pharmaceutical composition of the present invention can effectively improve the 2VO learning and memory function; In dizzy incubation period of influence experiment, be respectively correct 112.12 ± 16,127.41 ± 26,134.14 ± 31 the dizzy incubation periods in 12 weeks of oral liquid group of the present invention and 16 weeks, with the 2VO group notable difference, P＜0.05 are arranged relatively.Point out pharmaceutical composition of the present invention can effectively improve dizzy effect incubation period of 2VO rat.
In sum, this experimental result shows that this pharmaceutical composition has the chronic insufficient cerebral blood supply of improvement rat blood circulation, improves effects such as the dizziness that causes because of chronic cerebral ischemia and dysmnesia.
The specific embodiment
The present invention is further illustrated below in conjunction with embodiment, and following this embodiment only is used to the present invention is described and to the present invention without limits.
Embodiment 1
Prescription: Rhizoma Chuanxiong 127g, Radix Angelicae Dahuricae 42g, Rhizoma Et Radix Notopterygii 42g, Herba Asari 10g, Herba Menthae 84g, Radix Saposhnikoviae 15g, Radix Glycyrrhizae 21g, Folium Camelliae sinensis 63g, Radix Paeoniae Rubra 53g, Rhizoma Gastrodiae 21g, Flos Chrysanthemi 53g;
Preparation: Six-element Chinese medicines such as Rhizoma Chuanxiong, Rhizoma Et Radix Notopterygii, Herba Asari, Herba Menthae, Radix Saposhnikoviae, Flos Chrysanthemi are added 10 times of amounts of water, hydrodistillation is collected Aromatic water 800ml, aqueous solution after distillation device is in addition collected, medicinal residues and Radix Glycyrrhizae, the Radix Angelicae Dahuricae, Radix Paeoniae Rubra, Rhizoma Gastrodiae four flavors add 8 times of amounts of water and decoct twice, each decocting time is 1 hour, merge decocting liquid, filter; Filtering residue discards, and Folium Camelliae sinensis adds 12 times of amounts of fresh boiling water and soaks twice, and each soak time is 20 minutes, merge leachate, filter, the aqueous solution after filtrate and above-mentioned decocting liquid and the distillation merges, being evaporated to relative density is 1.14 (70 ℃), leaves standstill, and adds 2 times 95% ethanol after being cooled to room temperature, stir, cold preservation 24 hours makes precipitation, gets the supernatant concentrating under reduced pressure and reclaims ethanol, leave standstill, get supernatant and filter, it is 1.18 (room temperatures) that filtrate is concentrated into relative density, with above-mentioned Aromatic water with 0.8% tween 80 solubilising, add in the above-mentioned concentrated solution, stir, water is adjusted to 980ml, is being adjusted to 4.5～6.5 with 10%NaOH, adding the adjustment total amount to 1000ml, stir, leave standstill, filter, sterilization, promptly.
Embodiment 2
Prescription: Rhizoma Chuanxiong 50g, Radix Angelicae Dahuricae 20g, Rhizoma Et Radix Notopterygii 20g, Herba Asari 5g, Herba Menthae 50g, Radix Saposhnikoviae 10g, Radix Glycyrrhizae 10g, Folium Camelliae sinensis 40g, Radix Paeoniae Rubra 30g, Rhizoma Gastrodiae 10g, Flos Chrysanthemi 20g;
Preparation: said medicine is pulverized, crossed 100 mesh sieves, add refined honey, make honeyed pill.
Embodiment 3
Prescription: Rhizoma Chuanxiong 200g, Radix Angelicae Dahuricae 20g, Rhizoma Et Radix Notopterygii 80g, Herba Asari 5g, Herba Menthae 50g, Radix Saposhnikoviae 50g, Radix Glycyrrhizae 10g, Folium Camelliae sinensis 90g, Radix Paeoniae Rubra 30g, Rhizoma Gastrodiae 10g, Flos Chrysanthemi 20g;
Preparation: Six-element Chinese medicines such as Rhizoma Chuanxiong, Rhizoma Et Radix Notopterygii, Herba Asari, Herba Menthae, Radix Saposhnikoviae, Flos Chrysanthemi are added 10 times of amounts of water, hydrodistillation is collected Aromatic water 800ml, aqueous solution after distillation device is in addition collected, medicinal residues and Radix Glycyrrhizae, the Radix Angelicae Dahuricae, Radix Paeoniae Rubra, Rhizoma Gastrodiae four flavors add 8 times of amounts of water and decoct twice, each decocting time is 1 hour, merge decocting liquid, filter; Filtering residue discards, and Folium Camelliae sinensis adds 12 times of amounts of fresh boiling water and soaks twice, and each soak time is 20 minutes, merge leachate, filter, the aqueous solution after filtrate and above-mentioned decocting liquid and the distillation merges, being evaporated to relative density is 1.14 (70 ℃), leaves standstill, and adds 2 times 95% ethanol after being cooled to room temperature, stir, cold preservation 24 hours makes precipitation, gets the supernatant concentrating under reduced pressure and reclaims ethanol, leave standstill, get supernatant and filter, filtrate is condensed into extractum, adds above-mentioned Aromatic water, stir, add excipient starch, pelletize, granulate, go into the tablet machine tabletting then, make tablet.
Claims (5)
1. the application of following pharmaceutical composition in preparation treatment chronic insufficient cerebral blood supply medicine, the weight proportion of each flavour of a drug is as follows in the described pharmaceutical composition:
50～200 parts of Rhizoma Chuanxiongs, 20～80 parts of the Radixs Angelicae Dahuricae, 20～80 parts of Rhizoma Et Radix Notopterygiis, 5～20 parts of Herba Asaris, 50～150 parts of Herba Menthaes, 10～50 parts of Radix Saposhnikoviaes, 10～50 parts in Radix Glycyrrhizae, 40～90 parts of Folium Camelliae sinensis, 30～100 parts of Radix Paeoniae Rubra, 10～50 parts in Rhizoma Gastrodiae, 20～90 parts of Flos Chrysanthemis.
2. application according to claim 1, wherein the weight proportion of each flavour of a drug is as follows:
127 parts of Rhizoma Chuanxiongs, 42 parts of the Radixs Angelicae Dahuricae, 42 parts of Rhizoma Et Radix Notopterygiis, 10 parts of Herba Asaris, 84 parts of Herba Menthaes, 15 parts of Radix Saposhnikoviaes, 21 parts in Radix Glycyrrhizae, 63 parts of Folium Camelliae sinensis, 53 parts of Radix Paeoniae Rubra, 21 parts in Rhizoma Gastrodiae, 53 parts of Flos Chrysanthemis.
3. the application of pharmaceutical composition in the hypomnesis medicine that preparation treatment chronic insufficient cerebral blood supply causes, wherein the weight proportion of each flavour of a drug is as follows:
50～200 parts of Rhizoma Chuanxiongs, 20～80 parts of the Radixs Angelicae Dahuricae, 20～80 parts of Rhizoma Et Radix Notopterygiis, 5～20 parts of Herba Asaris, 50～150 parts of Herba Menthaes, 10～50 parts of Radix Saposhnikoviaes, 10～50 parts in Radix Glycyrrhizae, 40～90 parts of Folium Camelliae sinensis, 30～100 parts of Radix Paeoniae Rubra, 10～50 parts in Rhizoma Gastrodiae, 20～90 parts of Flos Chrysanthemis.
4. the application of pharmaceutical composition in the vertigo medicament that preparation treatment chronic insufficient cerebral blood supply causes, wherein the weight proportion of each flavour of a drug is as follows:
50～200 parts of Rhizoma Chuanxiongs, 20～80 parts of the Radixs Angelicae Dahuricae, 20～80 parts of Rhizoma Et Radix Notopterygiis, 5～20 parts of Herba Asaris, 50～150 parts of Herba Menthaes, 10～50 parts of Radix Saposhnikoviaes, 10～50 parts in Radix Glycyrrhizae, 40～90 parts of Folium Camelliae sinensis, 30～100 parts of Radix Paeoniae Rubra, 10～50 parts in Rhizoma Gastrodiae, 20～90 parts of Flos Chrysanthemis.
5. the application of pharmaceutical composition in the encephalopathy medicine that preparation treatment chronic insufficient cerebral blood supply causes, wherein the weight proportion of each flavour of a drug is as follows:
50～200 parts of Rhizoma Chuanxiongs, 20～80 parts of the Radixs Angelicae Dahuricae, 20～80 parts of Rhizoma Et Radix Notopterygiis, 5～20 parts of Herba Asaris, 50～150 parts of Herba Menthaes, 10～50 parts of Radix Saposhnikoviaes, 10～50 parts in Radix Glycyrrhizae, 40～90 parts of Folium Camelliae sinensis, 30～100 parts of Radix Paeoniae Rubra, 10～50 parts in Rhizoma Gastrodiae, 20～90 parts of Flos Chrysanthemis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100198288A CN100455316C (en) | 2004-06-30 | 2004-06-30 | Use of medicinal composition containing ligusticum wallichii for treating chronic brain blood supply deficiency |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100198288A CN100455316C (en) | 2004-06-30 | 2004-06-30 | Use of medicinal composition containing ligusticum wallichii for treating chronic brain blood supply deficiency |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1714850A true CN1714850A (en) | 2006-01-04 |
| CN100455316C CN100455316C (en) | 2009-01-28 |
Family
ID=35821211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100198288A Active CN100455316C (en) | 2004-06-30 | 2004-06-30 | Use of medicinal composition containing ligusticum wallichii for treating chronic brain blood supply deficiency |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100455316C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101919968A (en) * | 2009-06-09 | 2010-12-22 | 太极集团有限公司 | New application of traditional Chinese medicine composition for treating headache |
| CN109288972A (en) * | 2018-10-16 | 2019-02-01 | 李文本 | A kind of Chinese medicine composition |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1059106C (en) * | 1997-01-13 | 2000-12-06 | 中美合资四川太极制药有限公司 | Durg for curing headache and preparation technology thereof |
-
2004
- 2004-06-30 CN CNB2004100198288A patent/CN100455316C/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101919968A (en) * | 2009-06-09 | 2010-12-22 | 太极集团有限公司 | New application of traditional Chinese medicine composition for treating headache |
| CN109288972A (en) * | 2018-10-16 | 2019-02-01 | 李文本 | A kind of Chinese medicine composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100455316C (en) | 2009-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1872329A (en) | Application of medication composition of containing giant gen-seng in preparing medicine for treating insufficiency of blood supply for brain | |
| CN1872287A (en) | Application of medication composition of containing gastrodia tuber in preparing medicine for treating insufficiency of blood supply for brain | |
| CN100592918C (en) | Application of medication composition containing magnolia vine fruit in preparing medicine for treating insufficiency of blood supply for brain | |
| CN1872214B (en) | Application of medication composition of containing notoperygium root in preparing medication for treating chronic insufficiency of supplying blood for brain | |
| CN100455316C (en) | Use of medicinal composition containing ligusticum wallichii for treating chronic brain blood supply deficiency | |
| CN1872276B (en) | Application of medication composition of containing extractive of astragalus root in preparing medicine for treating insufficiency of blood supply for brain | |
| CN1872081A (en) | Application of kudzuvine root flavone in preparing medicine for treating chronic insufficiency of blood supply for brain | |
| CN100411652C (en) | Use of medicinal composition in preparing medicine for treating chronic brain blood supply deficiency | |
| CN1872187B (en) | Application of medication composition of containing astragalus root in preparing medication for treating chronic insufficiency of supplying blood for brain | |
| CN1872291A (en) | Application of medication composition of containing uncaria in preparing medicine for treating insufficiency of blood supply for brain | |
| CN1872288A (en) | Application of medication composition of containing eucommia in preparing medicine for treating insufficiency of blood supply for brain | |
| CN100548362C (en) | A kind of Rhizoma Typhonii pharmaceutical composition that contains is preparing the application for the treatment of in the chronic insufficient cerebral blood supply medicine | |
| CN100563699C (en) | A kind of application of pharmaceutical composition in the medicine of preparation treatment chronic insufficient cerebral blood supply that contains Rhizoma Ligustici | |
| CN1872297B (en) | Application of medication composition of Guangdong date in preparing medicine for treating chronic insufficiency of blood supply for brain | |
| CN100563692C (en) | A kind of application of pharmaceutical composition in the medicine of preparation treatment chronic insufficient cerebral blood supply that contains Magnetitum | |
| CN1872213B (en) | Application of medication composition of containing peach kernel in preparing medication for treating chronic insufficiency of supplying blood for brain | |
| CN1872170B (en) | Application of medication composition of containing corydalis tuber in preparing medication for treating chronic insufficiency of supplying blood for brain | |
| CN1872319B (en) | Application of medication composition of containing polygala root in preparing medicine for treating insufficiency of blood supply for brain | |
| CN1714851A (en) | Use of medicinal composition containing gastrodia elata for treating chronic brain blood supply deficiency | |
| CN1872290A (en) | Application of gastrodia tuber in preparing medicine for treating insufficiency of blood supply for brain | |
| CN1872145A (en) | Application of medication composition of containing caltrop in preparing medication for treating chronic insufficiency of supplying blood for brain | |
| CN1872154B (en) | Application of medication composition of containing Yunnan red sage root in preparing medication for treating chronic insufficiency of supplying blood for brain | |
| CN1872100A (en) | Application of extractive of ginkgo leaf in preparing medication for treating chronic insufficiency of supplying blood for brain | |
| CN1872286B (en) | Application of medication composition of containing notoginseng in preparing medicine for treating insufficiency of blood supply for brain | |
| CN100450539C (en) | Use of medicinal composition containing pilose antler for treating chronic brain blood supply deficiency |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191213 Address after: 117200 No. 1 Tianshili Avenue, Huanren Manchu Autonomous County, Benxi City, Liaoning Province Patentee after: Tianshili Northeast Modern Chinese Medicine Resources Co., Ltd. Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee before: Tasly Pharmaceutical Group Limited by Share Ltd |
|
| TR01 | Transfer of patent right |